Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2003 3
2004 4
2005 7
2006 9
2007 15
2008 16
2009 10
2010 19
2011 18
2012 16
2013 10
2014 15
2015 12
2016 10
2017 14
2018 3
2019 5
2020 6
2021 5
2022 10
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.
Watanabe K, Nojima M, Nakase H, Sato T, Matsuura M, Aoyama N, Kobayashi T, Sakuraba H, Nishishita M, Yokoyama K, Esaki M, Hirai F, Nagahori M, Nanjo S, Omori T, Tanida S, Yokoyama Y, Moriya K, Maemoto A, Handa O, Ohmiya N, Tsuchiya K, Shinzaki S, Kato S, Uraoka T, Tanaka H, Takatsu N, Nishida A, Umeno J, Nakamura M, Mishima Y, Fujiya M, Tsuchida K, Hiraoka S, Okabe M, Toyonaga T, Matsuoka K, Andoh A, Hirota Y, Hisamatsu T; J-COMBAT study group. Watanabe K, et al. Among authors: hirota y. J Gastroenterol. 2023 Oct;58(10):1015-1029. doi: 10.1007/s00535-023-02029-z. Epub 2023 Aug 10. J Gastroenterol. 2023. PMID: 37561155
Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities.
Suita A, Ohfuji S, Kasamatsu A, Kondo K, Nakata H, Kita T, Deguchi A, Fujimoto M, Iba K, Sakamoto H, Iwasaka K, Sakamoto N, Sakamoto H, Yodoi Y, Kido Y, Nakagama Y, Konishi A, Mukai E, Matsumoto K, Matsuura T, Kase T, Kakeya H, Fukushima W, Hirota Y. Suita A, et al. Among authors: hirota y. Vaccine X. 2023 Nov 22;15:100412. doi: 10.1016/j.jvacx.2023.100412. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38161985 Free PMC article.
Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case-Control Study.
Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, Sakamoto Y, Mukai N, Kinugasa Y, Shigyo M, Sonoda N, Tanaka M, Arase Y, Tanaka Y, Nakashima H, Irie S, Hirota Y. Hara M, et al. Among authors: hirota y. Vaccines (Basel). 2022 May 14;10(5):779. doi: 10.3390/vaccines10050779. Vaccines (Basel). 2022. PMID: 35632535 Free PMC article.
Comparison of self-reported symptoms in COVID-19 patients who had or had not previously received COVID-19 mRNA vaccination.
Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, Sakamoto Y, Mukai N, Kinugasa Y, Shigyo M, Sonoda N, Tanaka M, Arase Y, Tanaka Y, Nakashima H, Irie S, Hirota Y. Hara M, et al. Among authors: hirota y. Hum Vaccin Immunother. 2023 Aug 1;19(2):2226575. doi: 10.1080/21645515.2023.2226575. Hum Vaccin Immunother. 2023. PMID: 37357433 Free PMC article.
195 results